Environmental, Social and Governance (ESG)
Sihuan Pharmaceutical has always upheld its corporate vision of “becoming a competitive international pharmaceutical enterprise” and its corporate mission of “serving human health through innovation.” The Group integrates the concept of sustainable development into its strategic planning and business operations, actively fulfils its social responsibilities, shoulders its corporate responsibilities, continues to build a trusted corporate image, and puts the concept of sustainable development into practice through concrete action.
The Group integrates environmental, social and governance (ESG) considerations into its development strategy and continuously improves its ESG governance structure and operating mechanisms. It has established a three-tier ESG governance structure with the Board of Directors as the highest decision-making body, clearly defining ESG matters and management responsibilities to effectively promote participation in ESG initiatives across all departments.
Acting Responsibly, Sharing the Future
Health Responsibility
Ensuring Quality and Leading a Healthy Future
Green Responsibility
Keeping Safety in Mind and Fulfilling Green Commitments
Governance Responsibility
Laying a Solid Foundation and Fostering Integrity
Empowering Talents
Stimulating Talent Vitality and Sharing Development
Progressing Together
Working Responsibly for Industry Prosperity
Caring for Society
Supporting Public Welfare for a Better Life
Health Responsibility—Ensuring Quality and Leading a Healthy Future
Sihuan Pharmaceutical has always taken protecting the health of patients as its own responsibility. We have increased investment in research and development, actively introduced research and development talents, and promoted the long-term development of the Group through continuous technological innovation and product iteration. To promote product and technological innovation, we have increased our investment in research and development as well as set a target of no less than 30% of our annual revenue for investment in product research and development. We shall continue to monitor the achievement of this target annually. We continued to optimize the quality control system, strictly implement quality audits and assessments, strengthen product pharmacovigilance management, ensure product quality and safety, and also take practical actions to ensure patient medication safety. At the same time, in order to strengthen product research and development management and improve the level of quality control, we have set the Company’s overall product quality goals of “zero defects in product quality, 100% product qualification rate, and 100% customer satisfaction”, and continue to monitor the achievement of these goals annually. Besides, we have built a comprehensive customer service system, which dedicated ourselves to providing inclusive high-quality products and services. To further standardize marketing behavior, we insist on conducting marketing activities in an ethical, scientific and objective manner to ensure the safety of patients’ medication. The subsidiaries have passed GMP or GSP compliance inspections, and in 2024, Meiyan Space passed the ISO 13485 medical device quality management system recertification.
In 2024, the Group did not monitor any major safety risks related to product adverse events, nor did it cause any large-scale drug recalls related to adverse events. During the year, the Group had not experienced any incident of non-compliance concerning product and service information and labelling, or any incident of non-compliance concerning marketing communication. In addition, there had been no monetary loss as a result of legal proceedings associated with false marketing claims in the Group.